Brokerage firms have released their reports on shares of six companies today. Here’s what they have to say about LIC Housing Finance, Aster DM, Paytm, Vinati Organics, Divi’s Labs, and Gland Pharma, along with their target prices.
1. LIC Housing Finance
Nomura has given this stock a “BUY” rating but has reduced the target price from Rs 795 to Rs 700, suggesting a potential upside of about 25.5% from Monday’s closing price. They noted that Q3 profits were 4% above expectations, despite a slight decline in net interest income (NII). Loan distribution has slowed due to policy issues in some states, though the net interest margin (NIM) remained stable. HSBC has upgraded its rating from “Sell” to “Hold” with a target price of Rs 600, citing challenges in market share and pricing.
2. Aster DM Healthcare
HSBC has upgraded Aster DM to “BUY” with a target price of Rs 580, indicating a potential rise of around 24%. They mentioned that while Q3 results met expectations, increased taxes and costs affected profits. The company is focusing on expanding its hospital business and improving efficiency, which are positive signs for future growth.
3. Paytm
Bernstein has rated Paytm as “Outperform” with a target price of Rs 1,100, suggesting a potential increase of about 42%. They highlighted Paytm’s plan to acquire a 25% stake in a finance startup in Brazil. However, they also pointed out concerns about profitability in the Indian market and the potential distraction of expanding into new markets.
4. Vinati Organics
Motilal Oswal has given Vinati Organics a “Buy” rating with a target price of Rs 2,600, indicating a possible rise of around 49%. They noted that while EBITDA met estimates, profits were lower than expected due to reduced income from other sources. The company anticipates a 20% compounded annual growth rate (CAGR) over the next three years.
5. Divi’s Labs
Jefferies has recommended holding Divi’s Labs with a target price of Rs 6,280, suggesting a potential increase of about 6.7%. They reported that Q3 income met expectations and that the product mix was favorable for EBITDA. However, there are concerns about pricing pressure in the GX segment.
6. Gland Pharma
Jefferies has rated Gland Pharma as “Underperform” and has reduced the target price to Rs 1,350, forecasting a decline of about 11%. They noted that Q3 was disappointing for the company, with weak growth in the base business. Although there are expectations for improvement in Q4, challenges remain with the recently acquired CEnexi business.
